With the decrease of cancer incidences in a few major cancers, such as breast cancer and lung cancer, the incidence of esophageal cancer has still been climbing up steadily for the past decades, especially adenocarcinoma. Our views on esophageal cancer have been evolving as well. Modifications of the American Joint Committee on Cancer (AJCC) staging has been implemented in its recent edition in 2010. Diagnostic and follow-up standards are changing with more and more physicians and hospitals considering endoscopic ultrasound-guided biopsy as a minimal requirement for definitive diagnosis and accurate staging. In some large centers and by some physicians, laproscopic/ thorascopic biopsy are attempted to diagnose esophageal cancer with more accurate definitive staging. The widespread use of imaging studies, such as computed tomography and/or positon emission tomography, has improved the diagnosis in guiding the therapeutic options. In early stage esophageal cancer management, the acceptable modalities are still radiofrequency ablation, endoscopic mucosal resection, and photodynamic therapy. The advantages and disadvantages are discussed in this article. Surgical resection of early esophageal cancer of T2 or greater staging or N1 is still considered standard with potential to 'cure'; while minimal invasive laproscopic surgery showed acceptable improved effects and quality of life but are still limited to some tertiary centers. Multi-modality therapies of esophageal cancer in locally advanced stage, both resectable and unresectable, are discussed in this review. For operable diseases, neoadjuvant therapy, peri-surgery therapy, adjuvant therapy, chemotherapy, and/or radiation therapy are discussed. Unresectable esophageal cancer of both adenocarcinoma and squamous cell carcinoma as well as cancer with Her2/neu expression are also considered. The attached table listed the major landmark phase III clinical trials involving esophageal carcinoma. Metastatic cancer management, including the importance of quality of life management among the survivors is also examined.
Worldwide, it is the sixth leading cancer and fifth leading cause of death, with high incidence in Southern African countries and in Eastern Asia. 2, 3 Historically, more than 95 % of the esophageal malignancies were squamous cell carcinoma (SCC) and adenocarcinoma (EAC). SCC used to be the predominant type for most of the time in the 20th century. 4 However, for reasons unclear, the incidence of esophageal cancer has been increasing steadily for the past decades, with a commensurate decline of squamous cell cancers; 5 the diagnosis and staging modalities have been evolving as well.
The American Joint Committee on Cancer (AJCC) Staging Manual, 2010, 7th
Edition staging system provided separate stage grouping for squamous cell esophageal cancer, EAC of the esophagus and esophagogastric junction (EGJ or GEJ) with similar tumor size, nodal status, and metastasis categories (tumor, node, metastasis [TNM] staging). 6 On initial presentations, regardless of the histopathology, more than half of the esophageal cancers are at incurable locally advanced or metastatic disease, which makes esophageal cancer one of the most lethal malignancies. Tumor board discussion of the cases with multispecialty involvement has been accepted by majority of the hospitals. 
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The comparison between neoadjuvant chemotherapy versus neoadjuvant chemoradiation therapy was also studied, which showed nonsignificant better outcome in favor of chemoradiation group. 20 A large phase III trial studied the benefits of adjuvant chemotherapy using 5-FU/leucovorin/radiation. Results of this study suggested 9 months median survival benefits of adjuvant chemoradiation group (see Figure 2) . 21 A landmark study with more than 1,000 patient enrolled tried to answer the question which was the best chemo regimen combination for those unresectable esophageal cancers. Triplet chemo regimen combinations of ECF, ECX, EOF, and EOX (O=oxaliplatin; X=capecitabine, an oral fluoropyrimidine) were compared in parallel. The EOX group showed a small but statistically significant longer median survival versus other groups. 22 Based on these data, some physicians prefer the EOX combination over ECF as first-line therapy among unresectable locally advanced or metastatic esophagogastric cancers (see Figure 3) .
The incidence of squamous cell esophageal cancer has been decreasing for the past decades. Clinical trials were attempted to study the benefits of chemoradiation versus radiation alone in mainly unresectable squamous cell esophageal cancers. 23 Combination modality showed significant survival benefits with higher adverse events (see Figure 4) . The optimized dosage of radiation were also studied with the results showed better outcome in the low-dose protocol (50.4 Gy versus 64.8 Gy).
24
Her2/neu mutation testing is the first tumor marker in esophageal cancer that has had an impact in therapeutic guidance. Addition of trastuzumab showed clear survival benefits in Her2/neu-positive unresectable esophageal cancers. 25 Based on this trial, most oncologists consider the Her2/neu test part of the required diagnostic workup in guiding therapy.
The majority of the phase III landmark clinical trials are also described in Table 1 .
Unfortunately, with all the advancements, esophageal cancer is still one of the leading killers in malignancy. A majority of patients will eventually experience metastasis even with extensive treatment discussed above.
The long-term survival is very bad with <3 % in distant metastatic esophageal cancer patients. 26 Some of the metastatic diseases were diagnosed at restaging after treatment with surgery, chemotherapy, radiation therapy, or combination of the modalities.
During the patient encounter, the patients should be informed of the diagnosis as soon as possible and the discussion should be focused not only on the therapeutic modalities but also on the goal of the treatment.
Involvement of the palliative care service is also an important step during the conversation.
Clinical trial enrollment to explore the effects of novel agents and treatment modalities is the key in improvement of esophageal cancer management. Traditional cytotoxic agents, monoclonal antibodies, and tyrosine kinase inhibitors (TKIs) were all involved in the studies.
The need for a multi-institute international phase III study is obvious. The collaboration between clinical investigators and community oncologists as well as the collaboration among various subspecialty physicians, such as medical oncology, radiation oncology, and surgical oncology/thoracic surgery are critical in the investigational studies. n Please visit www.touchoncology.com for the complete review on esophageal cancer by Gibson et al. This will be available from the end of May 2013.
